

<http://www.pjbs.org>

**PJBS**

ISSN 1028-8880

**Pakistan  
Journal of Biological Sciences**

**ANSI***net*

Asian Network for Scientific Information  
308 Lasani Town, Sargodha Road, Faisalabad - Pakistan

## Cloning and Characterization of Serine-rich *Entamoeba histolytica* Protein Gene from an Iranian *E. histolytica* Isolate

<sup>1,4</sup>Sima Rasti, <sup>1</sup>Ali Haghighi, <sup>1,2</sup>Bahram Kazemi and <sup>3</sup>Mostafa Rezaian

<sup>1</sup>Department of Parasitology and Mycology,

Shaheed Beheshti University of Medical Sciences and Health Services, Tehran, Iran

<sup>2</sup>Cellular and Molecular Biology Research Center,

Shaheed Beheshti University of Medical Sciences and Health Services, Tehran, Iran

<sup>3</sup>Department of Parasitology and Mycology,

School of Public Health, Tehran University of Medical Sciences and Health services, Tehran, Iran

<sup>4</sup>Department of Parasitology, Kashan University of Medical Sciences and Health Services, Kashan, Iran

---

**Abstract:** *Entamoeba histolytica* causes amebic dysentery and amebic liver abscess, placing it second only to malaria, as a cause of death resulting from parasitic protozoa. Serine-rich *Entamoeba histolytica* Protein gene is an immunogenic, polymorphic protein and a candidate of vaccine that was cloned and characterized in this research. An Iranian *Entamoeba histolytica/Entamoeba dispar* isolate was cultivated in Robinson Medium. Total genomic DNA was isolated and *Entamoeba histolytica* strain has been distinguished by PCR with two sets of species-specific primers and SREHP gene was amplified by Nested-PCR. The purified PCR product was cloned into pBluscript via T/A cloning method. The recombinant plasmid was screened by Rusconis test, digested with BamHI restriction enzyme, which was approved by direct PCR and sequencing. The digested fragment of SREHP gene from recombinant plasmid was sequenced and showed a 666 base pair nucleotides as a new genotype of SREHP *Entamoeba histolytica*. The SREHP gene from Iranian isolate (SHR 10 IR) was different from HM1-IMSS cl.6 as well as all previously reported *Entamoeba histolytica* genotypes. Isolation of SREHP, expression of the gene, makes an opportunity to develop diagnostic kit, as well as determination of genetic variation of *Entamoeba histolytica* isolates in Iran.

**Key words:** Cloning, characterization, SREHP, *Entamoeba histolytica*, Iran

---

### INTRODUCTION

The protozoan pathogen *Entamoeba histolytica* is the causative agent of invasive intestinal and extraintestinal amoebiasis. It is estimated that more than 10% of people are infected with *Entamoeba dispar* and *E. histolytica* strains worldwide annually. Current WHO estimates of 40-50 million cases of amebic colitis and liver abscess and up to 100000 deaths per annum, placing it second only to malaria in mortality due to this protozoan parasite (Stanley, 2003; Ravdin and Stauffer, 2005; WHO/PAHO/UNESCO, 1997). *E. histolytica/E. dispar* is distributed through the world and is a substantial health risk in almost all worlds especially developing countries (Stanley, 2003). Serine rich *Entamoeba histolytica* Protein (SREHP) is highly immunogenic and appears to possess a number of conserved epitope. Among individuals with amebic liver abscess more than 80% have antibodies that

recognize the SREHP molecule (Stanley, 1997). There are different *E. histolytica* proteins that have formed the basis of recombinant antigen vaccines i.e., the SREHP, Gal/Gal NAC binding lectin, cysteine-proteinase and a 29 KDa antigen (Stanley, 1997; Martinez-Palomo *et al.*, 1998). Recombinant SREHP could be used in diagnosis of acute invasive amoebiasis (Myung *et al.*, 1992). Considering WHO recommendation on necessity of molecular studies on *E. histolytica* specific immunogenic compound for vaccine development, this research was done to clone and characterize of SREHP gene, for future expression of it and preparation recombinant protein to make diagnostic kit and amoebiasis vaccine study.

### MATERIALS AND METHODS

This research was conducted in Department of Parasitology and Mycology, School of Medicine,

---

**Corresponding Author:** Ali Haghighi, Department of Parasitology and Mycology,  
Shaheed Beheshti University of Medical Sciences and Health Services, Tehran, Iran

Shaheed Beheshti University of Medical Sciences and Health Services from February 2004 to October 2005.

**Entamoeba histolytica isolation:** An *E. histolytica*/*E. dispar* strain was isolated from a dysenteric patient in Shiraz, Fars Province, Iran in 2002 year. Xenic *in vitro* culture was established and maintained in Robinson medium as previously described (Robinson, 1968). Axenized *E. histolytica* HM-1: 1 MSS cl.6 strain was used as control and maintained in TYI-S-33 medium (Diamond *et al.*, 1978).

**DNA preparation and PCR analysis:** Total genomic DNA was isolated from culture as previously described (McPherson and Moller, 2000; Sambrook *et al.*, 2001). *E. histolytica* strain has been distinguished by PCR, using two sets of species-specific primers from locus 1-2, i.e., HSP1+HSP2 and DSP1+DSP2, (Table 1) (Zaki *et al.*, 2002). PCR was carried out in a 25  $\mu$ L reaction mixture containing 200 ng of DNA, 1.5  $\mu$ M concentration of primers, 1.5 mM MgCl<sub>2</sub>, 0.2 mM of deoxynucleoside triphosphate (dNTP) and 0.2  $\mu$ L of Taq DNA Polymerase (CinnaGen inc, Iran) with the following cycling parameters: (i) Taq activities at 94°C for 2 min; (ii) 35 cycles of denaturing at 94°C for 30 sec, annealing at 55°C for 30 sec and extension at 72°C for 60 sec and (iii) extension at 72°C for 10 min. PCR products were electrophoresed in 1.5% NuSieve 3:1 agarose (BioWhittaker Molecular Applications, Rockland, Maine). The result was visualized after staining with ethidium bromide (Sambrook *et al.*, 2001) in a UV transilluminator (UVIDoc Deluxe GAS 9000, England).

**Preparation of DNA insert:** External and internal primers of SREHP gene were designed based on SREHP gene obtained from HM-1: IMSS strain in GenBank database with accession no: M80910 and BamH1 site was designed at 5' end of internal primers (Table 1). A fragment of SREHP gene with about 700 bp was amplified using those primers by Nested-PCR. External PCR was carried out in a 50  $\mu$ L reaction mixture containing 200 ng of DNA, 2  $\mu$ M concentration of external primers, 1.5 mM MgCl<sub>2</sub>, 0.2 mM of dNTP and 0.3  $\mu$ L of Taq DNA Polymerase with the following cycling parameters: (I) Taq activities at 94°C for 2 min; (ii) 30 cycles of denaturing at 94°C for 30 sec, annealing at 50°C for 30 sec and extension at 72°C for 90 sec and (iii) extension at 72°C for 10 min. Internal PCR carried out in a 50  $\mu$ L reaction mixture containing 1  $\mu$ L of first PCR product, 2  $\mu$ M concentration of internal primers 1.5 mM MgCl<sub>2</sub>, 0.2 mM of dNTP and 0.3  $\mu$ L of Taq DNA Polymerase in the same external cycling parameters with the exception of annealing at 60°C for 30 sec. PCR

Table 1: Oligonucleotide primers

Primer name	Primer sequence 5' to 3'
HSP1 (Forward)	GAGTTCTCTTTTTATACTTTTATATGTT
HSP2 (Reverse)	ATTAACAATAAAGAGGGAGGT
DSP1 (Forward)	TTGAAGAGTTCACCTTTTTACTATA
DSP2 (Reverse)	TAAACAATAAAGGGGAGGG
EXT-SREHP (Sense)	GAGTGGAACATAATATCGATGA
EXT-SREHP (Antisense)	ATCCCAACTAAAGACTTTATT
SREHP-BamH1 (Sense)	GAGGATCCATGTTTCGCATTTTTATTGT
SREHP-BamH1 (Antisense)	GAGGATCCCTTAGAAGATGATAGCTAT

product was purified by Q-Biogen Gene clean II Kit (BIO101, Lajolla, Calif).

**T vector preparation:** pBluscript (pBSc) was extracted by GenElute™ plasmid mini prep kit (SIGMA, PLN-70) and T vector was prepared as previously described (Sambrook *et al.*, 2001).

**Gene cloning:** The PCR product of SREHP gene was cloned into the T- pBluscript -cloning vector. T/A cloning was done in 20  $\mu$ L volume, using insert-vector ratio of 4/1 with addition of 2  $\mu$ L T4 DNA ligase. The reaction incubated at 22°C for 3 h and was transformed into DH5a competent cells (Sambrook *et al.*, 2001). Recombinant plasmid was sequenced with appropriate internal primers in both directions using System analysis DNA Sequence 2000XL Beckman coulter, USA. The sequences obtained were manually edited and aligned using GENERUNR (Version 3.05).

**Screening:** Recombinant plasmids were detected by blue/white colonies screening method (Sambrook *et al.*, 2001) and was confirmed by Rusconis test. For the rusconis test a white colony was picked up and mixed with 12  $\mu$ L rusconis solution, centrifuged at 12000 rpm for 2 min. Eight microliter of supernatant was electrophoresed in 1% NuSieve 3:1 agarose and visualized after staining with ethidium bromide. Direct PCR was done using one of white colonies with internal primers under the above mentioned Nested-PCR conditions. The insert SREHP gene was also digested from the recombinant pBSc with BamH1 enzyme (McPherson and Moller, 2000; Sambrook *et al.*, 2001).

## RESULTS

Amplification of HM-1: IMSS with *E. histolytica* specific primers (HSP1, HSP2) gave the expected product of 340-bp. Iranian *E. histolytica*/*E. dispar* isolate (SHR 10 IR) showed a fragment of about 340 bp and identified as *Entamoeba histolytica* strain.

Both HM-1: IMSS cl6 and SHR 10 IR strains failed to amplify with *Entamoeba dispar* specific primers (DSP1, DSP2), while *E. dispar* AS 16 IR strain (Kobayashi *et al.*,




Fig. 1: Agarose gel electrophoresis of SREHP by Nested-PCR from Iranian *Entamoeba histolytica* isolate  
 Lane 1: 1 kb DNA ladder  
 Lane 2: SHR 10 IR isolate  
 Lane 3: positive control (HM1-IMSS)  
 Lane 4: negative control (DW)




Fig. 2: Agarose gel electrophoresis of digested SREHP gene from recombinant pBSc  
 Lane1: Enzyme digested recombinant pBSc shows a band of about 700-bp and the linear pBSc  
 Lane 2: The recombinant pBSc  
 Lane 3: 1 KbDNA ladder

2005) gave an expected band of about 430 bp as positive control. Nested-PCR product of SREHP gene gave a band of about 700 bp (Fig. 1).

Restriction enzyme analysis of recombinant plasmid by BamHI showed a band of the same size of the Nested-PCR product (about 700 bp) (Fig. 2). Direct PCR from

white colony was also approved the cloned SREHP gene. Finally DNA fragment of cloned SREHP was excised from recombinant plasmid, sequenced and an Open Reading Frame (ORF) of 666 bp was identified (Fig. 3).

### DISCUSSION

In the present study Serine-rich *E. histolytica* Protein gene of Iranian *E. histolytica* isolate was cloned and sequenced. In fact *E. coli* contained recombinant plasmid is the source for expression and preparation of SREHP

```

ATGTTTCGCAT TTTTATTGTT TATTGCATTC ACTAGTGCAA CTAATATCAT TCTTGATTTG
GATCAAGAAG TAAAAGATAC TAATATCTAC GGTGTATTTT TAAAGAACGA AGCTAGTCCT
GAAAAGCTTG AAGAAGCTGA AGAAAAAGAA AAAAGTAGCT CAGCAAACC AGAATCAAGT
TCAAATGAAG ATAATGAAGA TGATGAAGAT GAAAAAGCAA GTTCAAGTGA TAACTCAGAA
TCAAGCTCAA GTGATAAACC AGATAATAAA CCAGAAGCAA GTTCAAGTGA TAAACCAGAA
GCAAGTTCAA GTGATAAACC AGAAGCAAGT TCAAGTGATA AACCAGAAGT AAGTTCAAGT
GATAAACCAG ATAATAAACC AGAAGCAAGT TCAAGTGATA AACCAGATAA TAAACCAGAA
GCAAGCTCAA GTGATAAACC AGATAATAAA CCAGAAGCAA GCTCAAGTGA TAAACCAGAT
AATAAACCAG AAGCAAGCTC AACTAATAAA CCAGAAGCAA GCTCAACTAA TAAACCAGAA
GCAAGCTCAA CTAGTAATTC AAATGATAAA TCAGGAAGTA GTTCAGATAA CGATAATAAT
AACCTTGATG CTGCATCAAG TCCATTCATT GTTTTCTGTG CTATCATTAT AGCTATCATC
TTCTAA.
    
```

Fig. 3: Sequencing result of SREHP gene from Iranian *E. histolytica* isolate (SHR 10 IR). The repeat-containing region of the gene shown with rectangle




Fig. 4: Schematic representation of polymorphism in the repeat-containing region of the SREHP gene among SHR 10 IR and HM1-IMSS isolates. The numbers shown in the figure correspond to nucleotide numbers of SREHP of HM1-IMSS (GenBank /EMBL/DDBJ accession number M80910). Nucleotide and deduced amino acid sequences of tetra-, octa- and nonapeptide repeats are also shown

recombinant protein that is useful in diagnosis and prevention of amoebiasis.

SREHP gene sequences contain conserved regions and internal tandem dodecapeptides and octapeptides repeat units (Haghighi *et al.*, 2002). The 666 base pair SREHP gene of SHR 10 IR isolate was different from standard HM1-IMSS cl.6 strain as well as all previously reported *E. histolytica* genotypes (Fig. 4) (Clark and Diamond, 1993; Haghighi *et al.*, 2002, 2003). Antigenic variations in lengths, types and numbers of internal repeat units were observed in SREHP gene of SHR 10 IR isolate. Polymorphisms in lengths, types and numbers of internal repeat units were previously observed in locus 1-2 as well as in the repeat-containing region of serine-rich *E. histolytica* protein gene (Haghighi *et al.*, 2002 and 2003). Genotyping of the *E. histolytica* isolates could serve as a tool to fingerprint individual isolates and should help to determine geographic origin of isolates and routes of transmission (Haghighi *et al.*, 2002).

A WHO expert consultation on amoebae stressed the need for development for specific diagnosis of *E. histolytica* pathogen and *E. dispar* nonpathogen in clinical and epidemiological studies (WHO/PAHO/UNESCO, 1997). *E. histolytica* is rare in central of Iran

and *E. dispar* is the predominant species (96.9%) (Hooshyar *et al.*, 2003). Therefore in most cases anti-parasitic therapy is not necessary. Today antigen based ELISA kits (*E. histolytica* test II; TechLab, Blacksburg, Va.) or monoclonal antibodies against the serine-rich antigen of *E. histolytica* (Optimum S kit; Merlin Diagnostika, Bornheim-Hersel, Germany) are reported to be specific for *E. histolytica* diagnosis (Tanyuksel *et al.*, 2003). Preparation of recombinant protein such as Merlin Diagnostika kit for proper diagnosis of *E. histolytica* is necessary, for avoiding inappropriate usage of drug and drug resistance (Tanyuksel *et al.*, 2003). The purified recombinant SREHP as the target antigen in an ELISA test could prove useful in serodiagnosis of acute invasive amoebiasis (Myung *et al.*, 1992). Considering WHO recommendation on necessity of molecular studies on *E. histolytica* specific immunogenic compound, proteins associated with virulence have been identified, including lectin that mediates adherence to epithelial cells and SREHP are potential targets for anti amoebic vaccines. SREHP is a protective antigen and is a major candidate of vaccine for preventing of amebic liver abscess (Zhang and Cieslak, 1994a). Successful expression of Serine rich *E. histolytica* protein in an attenuated vaccine strain

*Salmonella typhi*, TY2 chi4297, combination vaccine designed to prevent both amoebiasis and typhoid fever was described (Zhang and Stanely, 1997). Cieslak demonstrated the feasibility of expressing recombinant amoebic proteins in attenuated *S. typhimurium* strains and a successful vaccination of animals with recombinant *E. histolytica* antigen was reported (Cieslak *et al.* 1993; Zhang and Cieslak, 1994b). This is the first report of cloning SREHP gene in Iran. The ability to isolate *E. histolytica* specific gene and to express the genes may provide useful reagents for studying the molecular basis of *E. histolytica* pathogenesis and future development of vaccine.

#### ACKNOWLEDGMENTS

The authors would like to thank Dr. Sahebani, Booshehr University of Medical Sciences and Health Services for providing Iranian *E. histolytica* isolate, Dr. Seiki Kobayashi for giving us HMI-IMSS cl.6 and Miss Sh. Farnia for maintaining the axenic standard strain. We also thank Miss Bandepour, Cellular and Molecular Biology Research Center, Shaheed Beheshti University of Medical Sciences and Health Services, for helpful guidance and Dr. Seyed Mahmoud Sadjjadi, Shiraz University of Medical Sciences and Health Services for his useful comments on the manuscript. This work was supported by a grant (6371, 2/1/2004) from Shaheed Beheshti University of Medical Sciences and Health Services to A. Haghighi.

#### REFERENCES

- Cieslak, P.R., T. Zhang and S.L. Stanley, 1993. Expression of a recombinant *Entamoeba histolytica* antigen in a *Salmonella typhimurium* vaccine strain. *Vaccine*, 11: 773-776.
- Clark, C.G. and L.S. Diamond, 1993. *Entamoeba histolytica*: A method for isolate identification. *Exp. parasitol.*, 77: 450-455.
- Diamond, L.S., Harlow and L.L. Bartgis, 1978. A new medium for the axenic cultivation of *Entamoeba histolytica* and other *Entamoeba*. *Trans. R. Soc. Trop. Med. Hyg.*, 72: 431-432.
- Haghighi, A., S. Kobayashi, T. Takeuchi, G. Masuda and T. Nozaki, 2002. Remarkable Genetic Polymorphism among *Entamoeba histolytica* Isolates from a Limited Geographic Area. *J. Clin. Microbiol.*, pp: 4081-4090.
- Haghighi, A., S. Kobayashi, T. Takeuchi, N. Thammapalerd and T. Nozaki, 2003. Geographic Diversity among Genotyping of *Entamoeba histolytica* field isolates. *J. Clin. Microbiol.*, 41: 3748-3756.
- Hooshyar, H., M. Rezaian and B. Kazemi, 2003. Distribution and Differential Diagnosis of *Entamoeba histolytica* from *Entamoeba dispar* by the PCR-RFLP Method in Central Iran. *Ann. Saudi Med.*, 23: 363-366.
- Kobayashi, S., E. Imai, A. Haghighi, S.A. Khalifa, H. Thachibana and T. Takeuchi, 2005. Axenic cultivation of *E. dispar* in newly design Yeast Extract -Iron-Gluconic Acid-Dihydroxyactone-Serum Medium. *J. Parasitol.*, 91: 1-4.
- Myung, K., D. Burch, T.F. Jackson and S.L. Stanley, 1992. Serodiagnosis of invasive amebiasis using recombinant *E. histolytica* antigen-based ELISA. *Arch. Med. Res.*, 23: 285-188.
- Martinez-Palomo, A. and E. Espinosal-Cantellano, 1998. Amoebiasis In: Topley and Wilson, Microbiology and Microbial Infectious. 9th Edn., Arnold.
- McPherson, M.J. and S.G. Moller, 2000. PCR: The Basics from Background to Bench. BIOS Scientific Publishers, Oxford, pp: 63-64.
- Robinson, G.L., 1968. The laboratory diagnosis of human parasitic amoebae. *Trans. R. Soc. Trop. Med. Hyg.*, 62: 285-294.
- Ravdin, J.I., W.M. Stauffer, 2005. *Entamoeba histolytica* (Amebiasis) In: Mandell, Douglas and Bennet's Principle and Practice of Infectious Diseases. 6th Edn., Churchill Livingstone Newyork, pp: 3097-3111.
- Sambrook, J., F. Fritsch and T. Maniatis, 2001. Molecular Cloning: A Laboratory Manual. 3rd Edn., Cold Spring Harbor NY: Cold Spring Harbor laboratory Press, pp: 6.9 -6.10, 8.35-8.36, 1.123-1.125, 1.116-1.118.
- Stanley, S.L., 1997. Progress toward development of vaccine for Amebiasis. *Clin. Microbiol. Rev.*, 10: 637-649.
- Stanley, S.L., 2003. Amoebiasis. *Lancet*, 361: 1025-1034.
- Tanyuksel, M. And W.A. Petri, 2003. Laboratory Diagnosis of Amebiasis. *Clin. Microbiol. Rev.*, 16: 713-726.
- WHO/PAHO/UNESCO Report, 1997. A consultation with experts on Amoebiasis Mexico city, Mexico. *Epidemiological Bulletin PAHO*, 18: 13-14.
- Zhang, T. and P.R. Cieslak, 1994a. Antibodies to the Serine rich *Entamoeba histolytica* Protein SREHP Prevent amebic liver abscess in Severe Combined Immunodeficient SCID Mice. *Parasite Immunol.*, 16: 225-230.
- Zhang, T. and P.R. Cieslak, 1994b. Protection of gerbils from amebic Liver abscesses by immunization with a recombinant *Entamoeba histolytica* antigen. *Infec. Immuno.*, 62: 1166-1170.
- Zhang, T. and S.L. Stanley, 1997. Expression of the Serine Rich *Entamoeba histolytica* Protein SREHP in the avirulent vaccine strain *Salmonella typhi* ty2 chi 4297: Safety and immunogenicity in mice. *Vaccine*, 15: 1319-22.
- Zaki, M., P. Meelu, W. Sun and C.G. Clark, 2002. Simultaneous Differentiation and Typing of *Entamoeba histolytica* and *Entamoeba dispar*. *J. Clin. Microbiol.*, 40: 1271-1276.